BUZZ-OmniAb drops after $30 mln equity financing

Reuters08-25
BUZZ-OmniAb drops after $30 mln equity financing

** Shares of biotech firm OmniAb OABI.O down 8.6% premarket to $1.69 after disclosing $30 mln equity raise

** Emeryville, California-based OmniAb announces it sold ~21.3 mln shares at $1.40 (or $1.85 for officer and director participation) in private placement for general corp purposes

** Financing included "top-tier new and existing investors" along with insider participation, co says

** OABI shares on Fri closed up 2.8% at $1.85, leaving them down ~48% YTD

** Co has ~122.7 mln shares outstanding for ~$227 mln market cap

** OmniAb's platform uses transgenic animals that have been genetically modified to produce human therapeutic candidates

** It went public in Nov 2022 after being spun off from Ligand Pharmaceuticals LGND.O and merging with SPAC backed by PE firm Avista Capital Partners

** All 8 analysts are bullish on OABI and median PT is $10, LSEG data reflects

** Leerink acted as sole agent for the private placement

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment